The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer

Cancer

Volumn 115, Issue 14, 2009, Pages 3189-3195

  Saphner, Tom ^a,d   Triest Robertson, Shirley ^b   Li, Hailun ^c   Holzman, Paul ^a  

^a St Mary's Hospital   (United States)

^b St Vincent Hospital Green Bay   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Green Bay Oncology   (United States)

Author keywords

Body mass index; Cirrhosis; Diabetes; Fatty liver disease; NASH; Nonalcoholic steatohepatitis; Tamoxifen; Tamoxifen induced hepatic steatosis

Indexed keywords

AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 68549109590     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24374     Document Type: Article

References (36)

1. Ahmed MH, Osman KA. Tamoxifen induced nonalcoholic steatohepatitis (NASH): has the time come for the oncologist to be a diabetologist. Breast Cancer Res Treat. 2006;97:223-224.
2. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced nonalcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf. 2007;6:1-4.
3. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185-194.
4. Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9:261-263.
5. Taniya T, Noguchi M, Tajiri K, et al. A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen. Gan No Rinsho. 1987;33:300-304.
6. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis - report of 3 cases. J Hepatology. 1995;23:95-97.
7. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis [letter]. Ann Intern Med. 1995;123:236.
8. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med. 1966;124:855-856.
9. Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet. 1999;353:36-37.
10. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced nonalcoholic steatohepatitis [letter]. Lancet. 1999;353:1802. (Pubitemid 29240397)
11. Cai Q, Bensen M, Green R, Kirchner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol. 2000;95:277-279. (Pubitemid 30041573)
12. Dray X, Tainturier MH, De La Lande P, Marty O, Mallet L. Cirrhosis with nonalcoholic steatohepatitis: role of tamoxifen. Gastroenterol Clin Biol. 2000;24:1122-1123. (Pubitemid 32002954)
13. Kotiloglu G, Aki ZS, Ozyilkan O, Kutlay, L. Tamoxifeninduced cirrhotic process. Breast J. 2001;7:442-443.
14. Lasso De La Vega MC, Zapater P, Such J, et al. Toxic hepatitis associated with tamoxifen use. A case report and literature review [in Spanish]. Gastroenterol Hepatol. 2002;25:247-250.
15. Ogawa Y Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer [letter]. Lancet. 1998;351:725. (Pubitemid 28105346)
16. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Non-alcoholic steatohepatitis [letter]. Lancet. 1999;354:1299-1300.
17. Murata Y Ogawa Y, Saibara T, et al. Unrecognized hepatic steatosis and nonalcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep. 2000;7:1299-1304.
18. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord. 2001;25:296-298. (Pubitemid 32158257)
19. Nemoto Y, Saibara T, Ogawa Y, et al. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med. 2002;41:345-350. (Pubitemid 34746176)
20. Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced nonalcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep. 2003;10:97-100.
21. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;180:129-134. (Pubitemid 36008699)
22. Coskun U, Toruner FB, Gunel N. Tamoxifen therapy and hepatic steatosis. Neoplasma. 2002;49:61-64.
23. Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S, Yoshida S. Follow-up CT findings of tamoxifen-induced nonalcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol Rep. 2003;10:1473-1478.
24. Gunel N, Coskun U, Toruner FB, et al. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr Med Res Opin. 2003;19:47-50. (Pubitemid 36378320)
25. Chu CH, Lin SC, Shih SC, Kao CR, Chou SY. Fatty metamorphosis of the liver in patients with breast cancer: possible associated factors. World J Gastroenterol. 2003;9:1618-1620.
26. Nagaie T, Hashimoto M, Kai M, et al. Changes in hepatic parenchymal ultrasound images in tamoxifen medication patients. Gan To Kagaku Ryoho. 2005;32:1925-1928.
27. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for nonalcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemo-prevention trial [serial online]. BMJ. 2005;330:932. (Pubitemid 40592310)
28. Liu CL, Huang JK, Cheng SP, Chang YC, Lee JJ, Liu TP. Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs. 2006;17:709-713.
29. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16:593-598.
30. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
31. McClain CJ, Mokshagundam SPL, Barve SS, et al. Mechanisms of nonalcoholic steatohepatitis. Alcohol. 2004;34:67-79.
32. Edmison J, McCullough AJ. Pathogenesis of nonalcoholic steatohepatitis: human data. Clin Liver Dis. 2007;11:75-104. (Pubitemid 46829977)
33. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:S17-S29.
34. Rivera CA. Risk factors and mechanisms of nonalcoholic steatohepatitis. Pathophysiology. 2008;15:109-114.
35. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219.
36. Day CP, James OFW. Steatohepatitis: a tale of 2 "hits?" Gastroenterology. 1998;114:842-845.